[1] |
Davies L, Welch HG, Increasing incidence of thyroid cancer in the United States, 1973-2002, JAMA, 2006, 295(18): 2164-2167. |
[2] |
Karam M, Gianoukakis A, Feustel PJ, et al. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun, 2003, 24(5): 489-495. |
[3] |
Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab, 2004, 89(4): 1666-1673. |
[4] |
Sawka AM, Thephamongkhol K, Brouwers M, et al. Clinical review 170: A systematic review and meta analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab, 2004, 89(8): 3668-3676. |
[5] |
朱瑞森, 余永利, 陆汉魁, 等. 分化型甲状腺癌术后131I治疗的必要性. 上海交通大学学报(医学版), 2006, 26(9): 1042-1043, 1055. |
[6] |
余永利, 罗全勇, 陈立波, 等. 分化型甲状腺癌术后131I治疗生存率分析. 中华核医学杂志, 2006, 26(5): 261-263. |
[7] |
Hershman JM, Edwards CL. Serum thyrotropin(TSH)levels after thyroid ablation compared with TSH levels after exogenous bovine TSH: implications for 131-I treatment of thyroid carcinoma. J Clin Endocrinol Metab, 1972, 34(5): 814-818. |
[8] |
Hackshaw A, Harmer C, Mallick U, et al. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab, 2007, 92(1): 28-38. |
[9] |
朱旭生, 邹德环, 佘立群, 等. 大剂量131I对分化型甲状腺患者术后剩余甲状腺组织的去除治疗. 中国肿瘤, 2007, 16(4): 279-281. |
[10] |
傅宏亮, 王辉, 吴靖川, 等. 影响分化型甲状腺癌术后131I清甲治疗疗效的因素分析. 中华核医学杂志, 2009, 29(3): 149-152. |
[11] |
Dorn R, Kopp J, Vogt H, et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med, 2003, 44(3): 451-456. |
[12] |
Samuel AM, Rajashekharrao B. Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for rem nant thyroid ablation after surgery. J Nucl Med, 1994, 35(12): 1944-1950. |
[13] |
Coover LR, Silberstein EB, Kuhn PJ, et al. Therapeutic131I in outpatients: a Simplified method conforming to the Code of Federal Regulations title10, part35.75. JNuclMed, 2000, 41(11): 1868-1875. |
[14] |
Cholewinski SP, Yoo KS, Klieger PS, et al. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J Nucl Med, 2000, 41(7): 1198-1202. |
[15] |
赵, 孙辉, 温强, 等. 分化型甲状腺癌术后131I清除剩余甲状腺及治疗甲癌转移灶的临床作用. 吉林医学, 2006, 27(2): 117-118. |
[16] |
Liel Y. Preparation for radioactive iodine administration in differentiated thyroid cancer patients. Clin Endocrinol(Oxf), 2002, 57(4): 523-527. |
[17] |
Grigsby PW, Siegel BA, Bekker S, et al. Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation. J Nucl Med, 2004, 45(4): 567-570. |
[18] |
Klain M, Ricard M, Leboulleux S, et al. Radioiodine therapy for papillary and follicular thyroid carcinoma. Eur J Nucl Med Mol Imaging, 2002, 29(Suppl 2): S479-S485. |
[19] |
Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab, 2006, 91(3): 926-932. |
[20] |
Barbaro D, Boni G, Meucci G, et al. Recombinant human thyroidstimulating hormone is effective for radioiodine ablation of postsurgical thyroid remnants. Nucl Med, 2006, 27(8): 627-632. |
[21] |
Sawka AM, Orlov S, Gelberg J, et al. Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma. Head Neck, 2008, 30(6): 693-700. |
[22] |
高再荣, 常伟, 崔坤炜, 等. 甲状腺乳头状癌术后刺激状态Tg预测131I清甲治疗后Tg水平的价值. 中华核医学杂志, 2009, 29(6): 156-159. |
[23] |
Verkooijen RB, Stokkel MP, Smit JW, et al. Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy. Eur J Nucl Med Mol Imaging, 2004, 31(4): 499-506. |
[24] |
Kumar A, Bal CS. Differentiated thyroid cancer. Indian J Pediatr, 2003, 70(9): 707-713. |
[25] |
王全林, 刘玲. 分化型甲癌术后131I首次去除残留组织效果的影响因素. 华西医学, 2001, 16(1): 55-56. |
[26] |
季鸿, 朱瑞森, 余永利, 等. 甲状腺癌术后131I首次清除剩余甲状腺疗效分析. 中华核医学杂志, 2001, 21(2): 91-92. |
[27] |
Simon D, Koehrle J, Reiners C, et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg, 1998, 22(6): 569-574. |
[28] |
Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer, 2005, 12(1): 49-64. |
[29] |
Cho JY. A transporter gene(sodium iodine symporter)for dual purposes in gene therapy: imaging and therapy. Curr Gene Ther, 2002, 2(4): 393-402. |